The activation of AMPK is followed by serine/threonine‐protein kinase mTOR (mTOR) inhibition leading to favourable phenotypic outcomes in cancer cells, such as reducing protein synthesis and proliferation rates, activation of autophagy and inhibition of inflammatory responses.23 Here, PRKAA1 is linked to cancer.